Dr. Zanos presented our latest pre-clinical data on the antidepressant mechanisms of action of ketamine during an invited speech at the European University of Cyprus. Our research provides compelling evidence that indirect activation of NMDA receptors, rather than their inhibition, may be the key mechanism responsible for ketamine’s rapid antidepressant effects. This challenges the conventional understanding and opens new avenues for therapeutic intervention.

Utilizing a multidisciplinary approach that integrates behavioral pharmacology, advanced neuroscience techniques, and molecular genetics, our team is unraveling complex neural pathways and molecular processes involved in depression. These innovative studies are not only enhancing our understanding of how ketamine exerts its effects but are also paving the way for the development of next-generation pharmacotherapies.

Our findings have significant implications for the treatment of depression, offering hope for more effective and faster-acting therapies. By leveraging these new insights, we aim to create better therapeutic strategies that can provide relief for individuals suffering from depression, particularly those who have not responded to traditional treatments.